Europe's liver disease treatment market is to USD 6.93 billion by 2033-Driven by Aging Population and Advances in Therapeutic Innovations | DataM Intelligence 2025

Europe's liver disease treatment market reached USD 2.59 billion in 2024 and is projected to grow to USD 6.93 billion by 2033, at an 11.56% CAGR, driven by aging population and rising liver disease prevalence.

Download Free sample report:-https://www.datamintelligence.com/download-sample/europe-liver-disease-treatment-market?pratik

Recent Product Launches in the US Market :

✅ August 2025: Novo Nordisk received accelerated FDA approval for Wegovy (semaglutide) to treat metabolic dysfunction-associated steatohepatitis (MASH), offering a novel treatment option for moderate to severe liver fibrosis patients.

✅ November 2025: GSK presented advancing pipeline data on bepirovirsen for chronic hepatitis B, showing promising efficacy in liver disease management.

✅ November 2025: Resolution Therapeutics announced positive early liver function improvements from their MATCH Phase II study using non-engineered macrophage therapy.

Recent Product Launches in the Japan Market :

✅ October 2025: Novo Nordisk filed for approval of Wegovy in Japan for MASH, aligning with global clinical trial results.

✅ November 2025: Ipsen disclosed late-breaking data on its therapies for liver disease at AASLD 2025, reflecting growing treatment options in the Japanese market.

✅ November 2025: Clinical studies on metabolic dysfunction-associated liver disease treatments are advancing rapidly, with Japan participating in global trials and regulatory submissions.

Growth Drivers:-

Government healthcare initiatives in France, Germany, and the UK, including hepatitis vaccination and early diagnosis programs, propel market growth.

Lifestyle factors such as increasing obesity, alcohol consumption, and viral infections contribute to higher demand for liver disease therapies.

Advances in antiviral, immunotherapy, and regenerative medicine enhance treatment efficacy and accessibility.

Pharmaceutical innovations, clinical trials, and robust reimbursement systems support therapy adoption, reducing liver disease mortality in Europe.

Market Segmentation Analysis

By Treatment Type

-Antiviral Drugs lead with the largest market share, driven by hepatitis and viral liver disease treatment demand.

-Targeted Therapy is the fastest-growing segment, fueled by advances in personalized medicine and oncology approaches for liver cancer.

-Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, and Chemotherapy drugs contribute to diverse therapeutic needs.

By Disease Type

-Hepatitis holds the largest market share, supported by vaccination and antiviral drug uptake.

-Non-Alcoholic Fatty Liver Disease (NAFLD) is rapidly increasing due to obesity and lifestyle factors, driving targeted therapy demand.

-Autoimmune Diseases, Liver Cancer, Genetic Disorders, and other liver conditions collectively fuel steady market growth.

By End User

-Hospitals dominate end-use with the majority share due to comprehensive treatment capabilities and infrastructure.

-Clinics and Ambulatory Surgery Centers are growing with expanding outpatient care and diagnostics.

-Other end users include specialized liver care centers and research institutions contributing to treatment adoption.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=europe-liver-disease-treatment-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

The Europe Liver Disease Treatment Market report would provide approximately

45 market data tables,
37 figures
105 pages.

Regional Insights:-

United States

The U.S. liver disease treatment market was valued at approximately USD 6.5 billion in 2024 and is projected to reach USD 12.9 billion by 2032, growing at a CAGR of about 9%.

-Growth is driven by increasing prevalence of chronic liver diseases, including hepatitis and fatty liver disease.

-Advances in antiviral and targeted therapies, coupled with rising healthcare spending, support market expansion.

-Government initiatives and increased awareness programs promote early diagnosis and treatment.

Japan

Japan's liver disease treatment market stood at approximately USD 1.2 billion in 2024 and is expected to grow to USD 2.8 billion by 2032 at a CAGR of around 10.5%.

-The aging population and lifestyle factors contribute to rising liver disease incidence.

-Adoption of innovative therapies and advanced diagnostics enhances treatment outcomes.

-National health policies support research and reimbursement for liver disease therapeutics.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/europe-liver-disease-treatment-market?pratik

Key Players:

Gilead Sciences, Inc.
Bristol-Myers Squibb
AbbVie Inc.
Intercept Pharmaceuticals
Vertex Pharmaceuticals
Allergan (now part of AbbVie)
Novartis
Johnson & Johnson
Merck & Co.
F. Hoffmann-La Roche

Key Highlights:

Gilead Sciences, Inc. reported strong growth driven by novel antiviral and NASH therapies addressing rising liver disease prevalence in Europe.

Bristol-Myers Squibb focuses on immunotherapy and targeted treatments, expanding clinical trials and approvals for liver cancer and fibrosis.

AbbVie Inc. leads with advanced hepatitis C and B antiviral therapies, contributing significantly to market revenue in 2024.

Intercept Pharmaceuticals achieved regulatory milestones with Obeticholic acid, the first approved therapy for NASH in several European countries.

Key development :-

Seladelpar (by Gilead Sciences) has been granted conditional marketing authorization by the European Commission for treatment of Primary Biliary Cholangitis (PBC) in the EU, offering a new option for patients who have inadequate response to UDCA.

Rezdiffra (resmetirom, by Madrigal Pharmaceuticals) received EU conditional approval for adults with non-cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis (MASH) with moderate-to-advanced fibrosis the first approved therapy in the region for this indication.

Iqirvo (elafibranor, by Ipsen) was conditionally approved in the EU for PBC a rare liver disease that hadn't seen a new treatment in nearly a decade

Request for 2 Days FREE Trial Access:

https://www.datamintelligence.com/reports-subscription?pratik

✅ Competitive Landscape

✅ Technology Roadmap Analysis

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Consumer Behavior & Demand Analysis

✅ Import-Export Data Monitoring

✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:

https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a renowned provider of market research, delivering deep insights

through pricing analysis, market share breakdowns, and competitive intelligence. The

company specializes in strategic reports that guide businesses in high-growth sectors such

as nutraceuticals and AI-driven health innovations.

To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter,

LinkedIn and Facebook.

This release was published on openPR.